Evidence map›Paper›PMID 41298346›Full record

ArticleBlood cancer journal2025

Genomic landscape and molecular subtypes of primary central nervous system lymphoma.

Shengjie Li, Danhui Li, Zuguang Xia, Jianing Wu, Jun Ren, Yingzhu Li, Jiazhen Cao, Ying Sun, Chengxun Li, Wenjun Cao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shengjie Li *Department of Neurosurgery, Huashan Hospital, Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China. lishengjie6363020@163.com.ORCID 0000-0002-6443-740X
Danhui Li *Department of Pathology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, 200127, China.
Zuguang Xia *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Jianing WuDepartment of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Jun RenDepartment of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Yingzhu LiDepartment of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Jiazhen CaoDepartment of Clinical Laboratory, Huashan Hospital, Fudan University, Shanghai, China.
Ying SunGenomiCare Biotechnology (Shanghai) Co. Ltd., Shanghai, China.
Chengxun LiENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China. licx21@m.fudan.edu.cn.ORCID 0000-0001-7318-8284
Wenjun CaoDepartment of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China. wgkjyk@aliyun.com.ORCID 0000-0001-6383-9012
Ying MaoDepartment of Neurosurgery, Huashan Hospital, Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China. maoying@fudan.edu.cn.ORCID 0000-0001-8055-115X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The genetic landscape and molecular subtypes of primary central nervous system lymphoma (PCNSL) remain inadequately characterized, presenting a major obstacle to the development of effective therapeutic strategies. We conducted a genomic study of 176 PCNSLs from five tertiary centers with long-term follow-up to expand the genomic landscape and identify new molecular subtypes. We first confirmed that the molecular subtyping of diffuse large B-cell lymphoma, as previously published, may not be fully applicable to Chinese PCNSL patients. We then identified (n = 58) and validated (n = 82) three prominent genetic subtypes related to different clinical and molecular features of PCNSL, and further confirmed by an independent external Chinese PCNSL cohort (n = 36). We called these BMIs (from the co-occurrence of mutations in two genes among BTG1, MYD88, and IRF4), which are associated with favorable outcomes; E3s (so-called EP300 mutations), which are associated with unfavorable outcomes; and UCs (unclassified, without characteristic mutations). Importantly, EP300 was mutated in more Asians (16.98%) than in Western PCNSLs (<4.53%), resulting in unfavorable outcomes independent of the specific mutation site. Our analysis comprehensively reveals the genomic landscape of Chinese PCNSL and emphasizes the clinical value of molecular classification for improving precision medicine strategies.

Indexed as

Central Nervous System NeoplasmsGenomicsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedMutationPrognosisYoung AdultBiomarkers, Tumor

Identifiers

PMID41298346
PMCPMC12783669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.